Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02071862
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:34.789265+00:00
Published At
2022-07-20T00:00:00+00:00
Record Updated At
2022-07-20
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Solid Tumors", "Triple-Negative Breast Cancer", "Non Small Cell Lung Cancer", "Renal Cell Carcinoma", "Mesothelioma", "Fumarate Hydratase (FH)-Deficient Tumors", "Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)", "Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors", "Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations", "Tumors Harboring Amplifications in the cMyc Gene"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-07-20"
protocolSection.identificationModule.nctId
"NCT02071862"
protocolSection.identificationModule.officialTitle
"Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Solid Tumors (protocolSection.conditionsModule.conditions)
  • Triple-Negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Non Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Mesothelioma (protocolSection.conditionsModule.conditions)
  • Fumarate Hydratase (FH)-Deficient Tumors (protocolSection.conditionsModule.conditions)
  • Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST) (protocolSection.conditionsModule.conditions)
  • Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors (protocolSection.conditionsModule.conditions)
  • Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations (protocolSection.conditionsModule.conditions)
  • Tumors Harboring Amplifications in the cMyc Gene (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.